Literature DB >> 33472175

The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors.

Liyu Wang1, Yu Liu1, Hengchang Liu2, He Tian1, Yalong Wang1, Guochao Zhang1, Yuanyuan Lei1, Liyan Xue3, Bo Zheng3, Tao Fan1, Yujia Zheng1, Fengwei Tan1, Qi Xue1, Shugeng Gao1, Chunxiang Li1, Jie He1.   

Abstract

Combination therapies based on photodynamic therapy (PDT) have received much attention in various cancers due to their strong therapeutic effects. Here, we aimed to explore the safety and effectiveness of a new mitochondria-targeting photodynamic material, TPE-IQ-2O, in combination therapies (combined with surgery or immunotherapy). The safety and effectiveness of TPE-IQ-2O PDT were verified with cytotoxicity evaluation in vitro and a zebrafish xenograft model in vivo, respectively. The effectiveness of TPE-IQ-2O PDT combined with surgery or immune checkpoint inhibitors (ICIs) was verified in tumor-bearing mice. Small animal in vivo imaging, immunohistochemistry, and flow cytometry were used to determine the underlying mechanism. TPE-IQ-2O PDT can not only reduce tumor recurrence in surgical treatment but also effectively improve the response to ICIs in immunotherapy without obvious toxicity. It was also found to ameliorate the immunosuppressive tumor microenvironment and promote the antitumor immunity induced by ICIs by increasing CD8+ tumor-infiltrating lymphocyte accumulation. Thus, TPE-IQ-2O PDT is a safe and effective antitumor therapy that can be combined with surgery or immunotherapy.

Entities:  

Keywords:  combination therapy; immunotherapy; photodynamic therapy; surgery; tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33472175      PMCID: PMC7835032          DOI: 10.18632/aging.202355

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  58 in total

1.  The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.

Authors:  André N Vis; Fritz H Schröder; Theodorus H van der Kwast
Journal:  Eur Urol       Date:  2006-01-06       Impact factor: 20.096

2.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

Review 3.  Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.

Authors:  Roberta Zappasodi; Taha Merghoub; Jedd D Wolchok
Journal:  Cancer Cell       Date:  2018-04-09       Impact factor: 31.743

4.  Recent advances of AIE dots in NIR imaging and phototherapy.

Authors:  Ruoyu Zhang; Yukun Duan; Bin Liu
Journal:  Nanoscale       Date:  2019-09-23       Impact factor: 7.790

5.  Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.

Authors:  Chunlin Li; Nengpan Zhang; Jundong Zhou; Chen Ding; Yaqing Jin; Xueyuan Cui; Kefeng Pu; Yimin Zhu
Journal:  Cancer Immunol Res       Date:  2017-12-07       Impact factor: 11.151

6.  A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy.

Authors:  Jianhong Lin; Weihong Zhang; Jian-Jun Zhao; Ariel H Kwart; Chun Yang; Dongdong Ma; Xiubao Ren; Yu-Tzu Tai; Kenneth C Anderson; Robert I Handin; Nikhil C Munshi
Journal:  Blood       Date:  2016-05-18       Impact factor: 22.113

7.  Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy.

Authors:  Chunbai He; Xiaopin Duan; Nining Guo; Christina Chan; Christopher Poon; Ralph R Weichselbaum; Wenbin Lin
Journal:  Nat Commun       Date:  2016-08-17       Impact factor: 14.919

Review 8.  Applications of Inorganic Nanomaterials in Photothermal Therapy Based on Combinational Cancer Treatment.

Authors:  Ji Wang; Xia Wu; Junjie Deng; Peng Shen; Jun Wang; Yidan Shen; Yan Shen; Thomas J Webster
Journal:  Int J Nanomedicine       Date:  2020-03-19

9.  Photodynamic therapy of melanoma skin cancer using carbon dot - chlorin e6 - hyaluronate conjugate.

Authors:  Songeun Beack; Won Ho Kong; Ho Sang Jung; In Hwan Do; Seulgi Han; Hyemin Kim; Ki Su Kim; Seok Hyun Yun; Sei Kwang Hahn
Journal:  Acta Biomater       Date:  2015-08-20       Impact factor: 8.947

10.  Flow cytometry analysis of Clostridium beijerinckii NRRL B-598 populations exhibiting different phenotypes induced by changes in cultivation conditions.

Authors:  Barbora Branska; Zora Pechacova; Jan Kolek; Maryna Vasylkivska; Petra Patakova
Journal:  Biotechnol Biofuels       Date:  2018-04-06       Impact factor: 6.040

View more
  4 in total

1.  Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.

Authors:  Tao Fan; Yu Liu; Hengchang Liu; Liyu Wang; He Tian; Yujia Zheng; Bo Zheng; Liyan Xue; Fengwei Tan; Qi Xue; Shungeng Gao; Chunxiang Li; Jie He
Journal:  Cancer Immunol Immunother       Date:  2021-05-11       Impact factor: 6.968

2.  LncRNA HOXA-AS3 Promotes the Progression of Pulmonary Arterial Hypertension through Mediation of miR-675-3p/PDE5A Axis.

Authors:  Zhong-Kui Li; Lu-Fang Gao; Xi-An Zhu; Dao-Kang Xiang
Journal:  Biochem Genet       Date:  2021-03-09       Impact factor: 1.890

Review 3.  Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.

Authors:  Hirohito Yamaguchi; Jung-Mao Hsu; Wen-Hao Yang; Mien-Chie Hung
Journal:  Nat Rev Clin Oncol       Date:  2022-02-07       Impact factor: 66.675

Review 4.  Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications.

Authors:  Ruolan Liu; Liyuan Peng; Li Zhou; Zhao Huang; Chengwei Zhou; Canhua Huang
Journal:  Antioxidants (Basel)       Date:  2022-04-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.